If any controlled substance appears in the listed bulk database, please ignore it, as we do not supply or offer controlled substances.
(R)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2S,3S)-2,3-dihydroxysuccinate
100% accuracy
of data
24/7 scientific
support
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

(R)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2S,3S)-2,3-dihydroxysuccinate

● In Stock

Catalogue No.:VE0011136
CAS No.:N/A
Mol. Formula:C26H31N3O8
Mol. Weight:513.54 g/mol

Additional information on (R)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2S | 3S)-2 | 3-dihydroxysuccinate

Parent drug

Silodosin

IUPAC Name

(R)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2S, 3S)-2, 3-dihydroxysuccinate

Synonyms

5-[(2R)-2-AMINOPROPYL]-1-[3-(BENZOYLOXY)PROPYL]-2,3-DIHYDRO-1H INDOLE-7-CARBONITRILE (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE MFCD16038449 3-[5-[(2R)-2-aminopropyl]-7-cyano-2,3-dihydroindol-1yl]propyl benzoate;(2R,3R)-2,3-dihydroxybutanedioic acid

Smiles

O=C(O)[C@@H](O)[C@H](O)C(O)=O.O=C(OCCCN1CCC2=C1C(C#N)=CC(C[C@H](N)C)=C2)C3=CC=CC=C3

InChI

InChI=1S/C22H25N3O2.C4H6O6/c1-16(24)12-17-13-19-8-10-25(21(19)20(14-17)15-23)9-5-11-27-22(26)18-6-3-2-4-7-18;5-1(3(7)8)2(6)4(9)10/h2-4,6-7,13-14,16H,5,8-12,24H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t16-;1-,2-/m10/s1

Description

The compound (R)-3-(5-(2-aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate (2S,3S)-2,3-dihydroxysuccinate is a highly characterized reference material that meets stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for a variety of applications, such as analytical method development, method validation (AMV), and Quality Control (QC), particularly in the context of Silodosin production. It is suitable for use in both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). Additionally, the product comes with a detailed Structure Elucidation Report (SER), ensuring its precision and reliability for comprehensive analytical use.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Products quotation
Name
Url
 
This field is hidden when viewing the form
This field is hidden when viewing the form